Tuesday, September 15, 2020 1:15:43 PM
Leo puts out a PR about Kevetrin's ability to arrest cell growth in AML cells. Kevetrin further shown to exhibit preferential cytotoxic activity against leukemia blast cells while largely not affecting the immune microenvironment, supporting a less toxic drug profile.
As a gene-based therapy, should Kevetrin demonstrate efficacy in clinical testing, its regulatory pathway to approval might be expedited. The Food and Drug Administration (FDA) has signaled strong support for development of gene therapies. Two gene therapies for cancers of the blood (Kymriah and Yescarta) were approved for genetically-driven diseases based primarily on results from mid-stage, single-arm, open-label clinical trials. FDA’s efficacy determination for Kymriah was based on 92 evaluable patients, and 108 evaluable patients for Yescarta.
https://www.yescartatecartusrems.com/
Yescarta/Tecartus used in conjunction within REMS program. Owned by Kite Pharma, Inc. a Gilead Company.
* Gilead owns Remdesivir which works great in conjunction with Brilacidin.
* Gilead is in the Lymphoma fighting business through Kite Pharma (Tecartus against MCL).
* Kevetrin shown to be a promising therapeutic against TP53-mutant AML.
* B has been proven to help against cytokines storms
* Gilead just purchased Immunomedics which is highly vested in the research to fight different types of cancers.
IPIX has the most promising p53 modulator and the most promising defensin-mimetic.
This is a match made in heaven!!!! Gilead can further enhance it's lymphoma fighting pipeline with Keventrin while utilizing Brilacidin in conjunction with Remdesivir and their AML and MCL drugs that have cytokines storm reactions.
I think Gilead is making a play!
Recent IPIX News
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 01:30:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2023 09:25:58 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/20/2023 09:05:44 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 01:00:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 08:15:25 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 09/28/2023 01:00:08 PM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM
Element79 Gold Corp Announces 2024 Clover Work Plans & Nevada Portfolio Updates • ELMGF • Sep 10, 2024 11:00 AM
Nightfood Holdings Inc. Completes Major Step on Uplist Journey by Closing Strategic All-Stock Acquisition of CarryoutSupplies.com • NGTF • Sep 10, 2024 8:15 AM
Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • ELEM • Sep 9, 2024 9:34 AM